Biocon’s arm gets nod for Posaconazole Delayed-Release tablets from USFDA

08 Feb 2022 Evaluate

Biocon’s subsidiary company -- Biocon Pharma has received approval of its ANDA for Posaconazole Delayed-Release tablets from the United States Food and Drug Administration (USFDA). This product is indicated for use in the prevention of certain fungal infections in patients with severely weakened immune systems and is available in 100mg strength. This approval further adds to Biocon’s portfolio of vertically integrated complex drug products.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

379.70 10.60 (2.87%)
25-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.85
Dr. Reddys Lab 1301.90
Cipla 1243.90
Zydus Lifesciences 903.60
Lupin 2347.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×